Scynexis (SCYX) Total Non-Current Liabilities (2013 - 2026)
Scynexis (SCYX) posted Total Non-Current Liabilities of $17.4 million for Q1 2026, up 133.78% on a QoQ basis from $7.5 million in Q4 2025, and up 41.81% year-over-year from $12.3 million in Q1 2025.
Scynexis (SCYX) Total Non-Current Liabilities (2013 - 2026) Analysis & Trends
Scynexis' Total Non-Current Liabilities history runs 14 years deep, the most recent figure standing at $17.4 million for Q1 2026.
- Quarterly Total Non-Current Liabilities rose 41.81% year-over-year to $17.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.4 million (up 41.81% YoY) and the FY2025 annual result came in at $7.5 million, down 72.97% from the prior year.
- Total Non-Current Liabilities was $17.4 million for Q1 2026 at Scynexis, up from $7.5 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $85.1 million in Q2 2022 and bottomed at $7.5 million in Q4 2025.
- A 5-year average of $36.5 million and a median of $31.7 million in 2023 frame the typical range for Total Non-Current Liabilities.
- Annual changes were most pronounced in 2025 — Total Non-Current Liabilities tumbled 72.97% — and 2026, when it jumped 41.81%.
- Scynexis' Total Non-Current Liabilities stood at $66.0 million in 2022, then tumbled by 48.82% to $33.8 million in 2023, then fell by 18.37% to $27.6 million in 2024, then tumbled by 72.97% to $7.5 million in 2025, then surged by 133.78% to $17.4 million in 2026.
- Business Quant data shows SCYX's Total Non-Current Liabilities at $17.4 million in Q1 2026, $7.5 million in Q4 2025, and $11.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 14.92 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 18.28 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 33.47 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 599.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 20.09 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.24 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.26 Bn |
| 10 | Scynexis | 21.55 Mn | -15.20 Mn | - | 17.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 17.42 Mn |
| Dec 31, 2025 | 7.45 Mn |
| Sep 30, 2025 | 11.10 Mn |
| Jun 30, 2025 | 13.33 Mn |
| Mar 31, 2025 | 12.28 Mn |
| Dec 31, 2024 | 27.57 Mn |
| Sep 30, 2024 | 29.30 Mn |
| Jun 30, 2024 | 29.40 Mn |
| Mar 31, 2024 | 31.95 Mn |
| Dec 31, 2023 | 33.77 Mn |
| Sep 30, 2023 | 31.96 Mn |
| Jun 30, 2023 | 31.69 Mn |
| Mar 31, 2023 | 59.89 Mn |
| Dec 31, 2022 | 65.98 Mn |
| Sep 30, 2022 | 67.35 Mn |
| Jun 30, 2022 | 85.07 Mn |
| Mar 31, 2022 | 64.71 Mn |
| Dec 31, 2021 | 75.23 Mn |
| Sep 30, 2021 | 70.17 Mn |
| Jun 30, 2021 | 64.36 Mn |